RBI maintains status quo on interest rates at 5.25% with a neutral stance, projecting CPI inflation to align with the 4% target by Q1 FY27.
Team Sahi
Market snapshot: The Reserve Bank of India's Monetary Policy Committee (MPC), led by Governor Sanjay Malhotra, concluded its February 2026 review by keeping the policy repo rate unchanged at 5.25%. Maintaining a 'Neutral' stance, the central bank signaled confidence in the domestic growth trajectory while closely monitoring inflation revisions for the upcoming fiscal year. This decision follows a cumulative reduction of 125 basis points in the repo rate since February 2025, marking a transition into a 'wait-and-watch' phase as the economy absorbs past easing measures.
Summary: RBI maintains status quo on interest rates at 5.25% with a neutral stance, projecting CPI inflation to align with the 4% target by Q1 FY27.
The RBI's move to pause at 5.25% suggests that the aggressive easing cycle has peaked. By projecting a 4% inflation handle for Q1 FY27, the central bank is anchoring market expectations toward its long-term stability mandate. Investors should note the 'Neutral' stance; it provides the RBI flexibility to manage liquidity through VRR (Variable Rate Repo) and OMO (Open Market Operations) without committing to further rate cuts in the near term. The transition to the new CPI base (2024=100) next week will be the next critical data pivot for fixed-income markets.
A stable interest rate environment paired with controlled inflation projections creates a 'Goldilocks' scenario for Indian equities, though bond yields may face short-term pressure due to liquidity constraints.
High Performance Trading with SAHI.
Related
Recent
Fed's 2026 Outlook: Economic Resilience Meets Persistent Inflationary Pressures
Geopolitical Brinkmanship: Trump-Iran Tensions and the Indian Market Outlook
Zydus Lifesciences Disrupts Respiratory Care with Indiaās First Drug-Free Device 'Pepair' at ā¹990
Infosys Pivots to 'AI-First' Era: New Framework Targets $300 Billion Market Opportunity
Zydus Lifesciences Disrupts Respiratory Care with Indiaās First Affordable Drug-Free Device āPepairTMā at ā¹990